Injectable Methylcobalamin Dosing for Vitamin B12 Deficiency
The dosing of intramuscular methylcobalamin depends critically on whether neurological involvement is present: for patients with neurological symptoms, administer 1000 mcg (1 mg) intramuscularly on alternate days until no further improvement occurs, then 1000 mcg every 2 months; for patients without neurological involvement, give 1000 mcg intramuscularly three times weekly for 2 weeks, followed by lifelong maintenance of 1000 mcg every 2-3 months.
Critical First Step: Assess for Neurological Involvement
Before initiating treatment, determine if neurological symptoms are present, as this fundamentally changes the dosing regimen 1:
Neurological red flags include:
- Unexplained sensory symptoms (numbness, tingling, burning)
- Motor weakness or gait disturbances
- Balance problems or ataxia
- Cognitive changes or memory impairment
If any neurological symptoms are present, seek urgent specialist advice from neurology and hematology immediately 1.
Treatment Protocols
For Patients WITH Neurological Involvement
Loading phase: 1000 mcg (1 mg) intramuscularly on alternate days until there is no further clinical improvement 1
Maintenance phase: 1000 mcg intramuscularly every 2 months for life 1
This aggressive initial dosing is essential because neurological damage from B12 deficiency can become irreversible if allowed to progress beyond 3 months 2. The alternate-day dosing ensures rapid tissue saturation and halts progression of subacute combined degeneration of the spinal cord.
For Patients WITHOUT Neurological Involvement
Loading phase: 1000 mcg intramuscularly three times weekly for 2 weeks 1
Maintenance phase: 1000 mcg intramuscularly every 2-3 months for life 1
Important Clinical Considerations
Route of Administration Matters
Avoid intravenous administration - the IV route results in almost all vitamin B12 being lost in urine, making it therapeutically ineffective 2. Use intramuscular or deep subcutaneous injection only 2.
Why Not Oral Methylcobalamin?
While the guidelines reference hydroxocobalamin (the standard B12 form), the FDA label for methylcobalamin specifically states that oral forms are not dependable for treating B12 deficiency with malabsorption 2. The evidence shows oral B12 requires very high doses (1000-2000 mcg daily) and may not be adequate when malabsorption is the underlying cause 3, 4. For neuropathy specifically, research suggests 500 mcg IM three times weekly produces higher serum levels than 1500 mcg once weekly 5.
Critical Pitfall: Folic Acid Interaction
Never give folic acid before treating B12 deficiency 1. Folic acid can mask the hematologic manifestations of B12 deficiency while allowing irreversible neurological damage to progress, potentially precipitating subacute combined degeneration of the spinal cord 1, 2. If folate deficiency coexists, treat B12 first, then add folic acid 5 mg daily for at least 4 months 1.
Monitoring During Treatment
In the first 48 hours of treatment, monitor serum potassium closely and replace if necessary, as rapid hematologic response can cause hypokalemia 2.
For the first week of treatment, check:
- Hematocrit and reticulocyte count daily from days 5-7
- Continue monitoring frequently until hematocrit normalizes
- If reticulocytes don't increase or don't reach at least twice normal levels while hematocrit remains below 35%, reassess diagnosis and treatment 2
Special Populations
Patients with pernicious anemia: Require lifelong monthly injections - failure to continue treatment will result in return of anemia and irreversible nerve damage 2.
Post-bariatric surgery patients: Follow the same protocols as above, as these patients have permanent malabsorption 1.
Crohn's disease with >20 cm ileal resection: Prophylactic 1000 mcg monthly indefinitely, even without documented deficiency 6.
Individualization of Maintenance Dosing
While guidelines recommend every 2-3 months for maintenance, clinical experience suggests up to 50% of patients require more frequent dosing (ranging from every 2-4 weeks) to remain symptom-free 3. The key principle: titrate based on symptom resolution, not serum B12 levels - once on replacement therapy, serum B12 measurements become unreliable for guiding frequency 3.
If symptoms recur before the next scheduled injection, shorten the interval rather than increasing the dose per injection.